Resveratrol Metabolism in a Non-Human Primate, the Grey Mouse Lemur (*Microcebus murinus*), Using Ultra-High-Performance Liquid Chromatography–Quadrupole Time of Flight

Marie-Claude Menet1*, Julia Marchal2, Alexandre Dal-Pan2, Méryam Taghi1, Valérie Nivet-Antoine3,4, Delphine Dargère1, Olivier Laprévote1,5, Jean-Louis Beaudex3,6, Fabienne Aujard2, Jacques Epelbaum7, Charles-Henry Cottart3,6

1 EA 4463, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 2 Mécanismes Adaptatifs et Evolution, UMR 7179, Centre National de la Recherche Scientifique, Muséum National d’Histoire Naturelle, Bruxelles, France, 3 EA 4466, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 4 Service de Biochimie, AP-HP, Hôpital Européen Georges Pompidou, Paris, France, 5 Service de Toxicologie biologique, AP-HP, G.H. Lariboisière – Saint Louis – Fernand Widal, Paris, France, 6 Centre de Psychiatrie et Neuroscience, UMR 894 Inserm, Faculté de Médecine, Université Paris Descartes, Paris, France

*E-mail: marie-claude.menet@parisdescartes.fr*

**Abstract**

The grey mouse lemur (*Microcebus murinus*) is a non-human primate used to study the ageing process. Resveratrol is a polyphenol that may increase lifespan by delaying age-associated pathologies. However, no information about resveratrol absorption and metabolism is available for this primate. Resveratrol and its metabolites were qualitatively and quantitatively analyzed in male mouse-lemur plasma (after 200 mg.kg⁻¹ of oral resveratrol) by ultra-high performance liquid chromatography (UHPLC), coupled to a quadrupole-time-of-flight (Q-TOF) mass spectrometer used in full-scan mode. Data analyses showed, in MS² mode, an ion common to resveratrol and all its metabolites: m/z 227.072, and an ion common to dihydro-resveratrol metabolites: m/z 229.08. A semi-targeted study enabled us to identify six hydrophilic resveratrol metabolites (one diglucuronono-conjugated, two monoglucuronono-conjugated, one monosulfo-conjugated and two both sulfo- and glucurono-conjugated derivatives) and three hydrophilic metabolites of dihydro-resveratrol (one monoglucuronono-conjugated, one monosulfo-conjugated, and one both sulfo- and glucurono-conjugated derivatives). The presence of such metabolites has been already detected in the mouse, rat, pig, and humans. Free resveratrol was measurable for several hours in mouse-lemur plasma, and its two main metabolites were trans-resveratrol-3-O-glucurone and trans-resveratrol-3-sulfate. Free dihydro-resveratrol was not measurable whatever the time of plasma collection, while its hydrophilic metabolites were present at 24 h after intake. These data will help us interpret the effect of resveratrol in mouse lemur and provide further information on the inter-species characteristics of resveratrol metabolism.

**Citation:** Menet M-C, Marchal J, Dal-Pan A, Taghi M, Nivet-Antoine V, et al. (2014) Resveratrol Metabolism in a Non-Human Primate, the Grey Mouse Lemur (*Microcebus murinus*), Using Ultra-High-Performance Liquid Chromatography–Quadrupole Time of Flight. PLoS ONE 9(3): e91932. doi:10.1371/journal.pone.0091932

**Editor:** Markus M. Heimesaat, Charité, Campus Benjamin Franklin, Germany

**Received** October 28, 2013; **Accepted** February 18, 2014; **Published** March 24, 2014

**Copyright:** © 2014 Menet et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported by a “BQR” grant from the Paris Descartes University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

* E-mail: marie-claude.menet@parisdescartes.fr

**Introduction**

Resveratrol is a dietary polyphenol compound present in numerous plants, especially grapes. *In vitro* and *in vivo* studies have highlighted that resveratrol could display properties that could be applied to human health. Among them, resveratrol acts on glucose and lipid metabolism [1] and may limit the development of cardiovascular [2,3] and neurodegenerative [4,5] diseases, as well as cancer [6]. Moreover, even though it is still controversial, resveratrol appears to mimic calorie restriction, at least in part, by acting through the sirtuin pathway [7]. Indeed, resveratrol can increase the lifespan of numerous species, from yeast to mice [8]. When ingested *per os*, resveratrol, which is a lipophilic compound, is well absorbed, and rapidly metabolized in the intestine and liver into hydrophilic metabolites, which are then eliminated in the urine. After oral intake, the small quantity of non-metabolized resveratrol in plasma has raised some doubts about its capacity to display physiological effects. Moreover, intestinal gut microflora may hydrogenate resveratrol's double bond to form dihydro-resveratrol (DHR), which can then be absorbed and metabolized [9]. However, the sulfo- and glucuronono-metabolites of resveratrol are mainly represented in plasma and could sustain their own activities, although resveratrol metabolism may vary from one species to another [10]. Up until now, the identification and assessment of resveratrol metabolites has been performed in several species, such as the mouse [11], rat [12], dog [13], pig [14], and humans [15,16].

The grey mouse lemur (*Microcebus murinus*), a small heterothermic primate, is a relevant model for studying ageing [17,18,19], as it has a median lifespan of 5.7 years for males,
and a maximal lifespan of 11 years. These data are based on those from the Brunoy breeding colony [10], in which mouse-lemurs lived for two-to-three times longer than mammals of equivalent body mass.

Grey mouse lemurs are phylogenetically closer to humans than rodents; therefore, they are used to test new dietary or pharmacological strategies to improve lifespan and decrease age-associated pathologies [20,21]. Available data show that resveratrol treatment can affect metabolism [20,22], cognitive performance [17], and the sleep–wake cycles [23] of this lemur. More precisely, this primate has marked seasonal metabolic rhythms: it has a resting metabolic rate and body weight that fluctuates seasonally. In 2010, a study by Dal-Pan et al. reported on the effect of acute resveratrol treatment (200 mg.kg$^{-1}$ day$^{-1}$) [22]. The authors regularly measured body temperature, body weight gain, and resting metabolic rate of treated animals. After a 4-week of treatment, they found an immediate effect: the treated animals had reduced food intake by 13% and had increased their resting metabolic rate (which was part of their energy expenditure) by 29%. Thus, ingestion of resveratrol allowed these animals to significantly reduce weight, while they would normally tend to gain weight and store-up energy before the breeding season. These results provide new information on the effects of resveratrol on energy metabolism and the control of body weight in primates. However, no information on resveratrol absorption and metabolism in Microcebus murinus is currently available.

The aim of the present study was to identify and assess resveratrol metabolites in the plasma of mouse lemurs after oral intake of 200 mg.kg$^{-1}$ of resveratrol, using ultra-high-performance liquid chromatography (UHPLC) coupled to a high-resolution mass-spectrometer, quadrupole-time of flight (Q-TOF) [11].

**Materials and Methods**

1. **Chemicals and materials**

   A reference standard (Fig. 1) of trans-resveratrol (99%, w/w) was purchased from Sigma (Saint-Quentin-Fallavier, France). Trans-resveratrol-$^{13}$C$_6$ was obtained from LGC Standard (Molsheim, France). Reference standards (Fig. 1) of trans-resveratrol-3-O-ß-D-glucuronide, trans-resveratrol-4’-O-ß-D-glucuronide, trans-resveratrol-3-sulfate, trans-resveratrol-3-O-ß-D-glucuronide-D$_4$, trans-resveratrol-4’-O-ß-D-glucuronide-D$_4$, and trans-resveratrol-3-sulfate-D$_4$ were provided by Spi Bio, Bertin Pharma (Montigny le Bretonneux, France). Because of the low stability of resveratrol and its derivatives in ultraviolet light [24], all reference analytes and internal standards were stored in the dark at $-20^\circ$C.

   HPLC-grade acetonitrile (ACN) and methanol (MeOH) were purchased from Merck (Nogent-sur-Marne, France). Formic acid ($\geq$99% w/w), HPLC grade, was obtained from Fischer Scientific (Illkirch, France). All other chemicals were of analytical grade, and the solvents used were of chromatographic grade. All water was prepared with a Milli-Q water purification system (Millipore, Molsheim, France). Resveratrol (98.3%, w/w, Sequoia Research Products, UK) was used for the gavage of mouse lemurs.

2. **Study design**

   The grey mouse lemurs were born in the laboratory breeding colony of Brunoy (Muséum National d’Histoire Naturelle, UMR 7179 CNRS/MNHN, France; Agreement DDPP # D91-114-1). All experiments were performed in accordance with the Principles of Laboratory Animal Care (National Institutes of Health publication 86-23, revised 1985) and the European Communities Council Directive (86/609/EEC). Regarding the environmental enrichment and housing of the grey-mouse lemurs used in this study, in order to minimize social influences during the different experiments, animals were housed individually in 1 m$^3$ cages, provided with two wooden nests and separated from each other by metallic partitions. The grey mouse lemur is a nocturnal primate that shows high levels of locomotor activity, thus we provided in each cage, many natural tree branches. The research was conducted under the authorization number 91-305 from the “Direction Départementale des Services Vétérinaires de l’Essonne” and the Internal Review Board of the UMR 7179.

   In accordance with the recommendations of the Weatherall report, “The use of non-human primates in research”, special attention was paid to the welfare of the animals during this work to minimize nociception (Weatherall FR D. 2006. The use of non-human primates in research, The Weatherall report).

   General conditions of captivity were consistently maintained. Animals were exposed to ambient room temperature (24–26°C) and a relative humidity of 55%. Animals were fed ad libitum every 2 days: fresh fruits (apples and banana), and a homemade mixture of white cheese, ginger bread, baby cereal, milk, and egg were provided. Water was given ad libitum. These mouse lemurs ($n=20$), weighing 98.2±42.3 g, were divided into five groups. One group was not treated with resveratrol and was used as a control ($n=3$); the other four groups were given resveratrol and plasma was collected at 1 ($n=4$), 2 ($n=5$), 6 ($n=4$), or 24 h ($n=4$) after intake of resveratrol. All lemurs used in this study were males. It should be noted that NO grey mouse lemur has been sacrificed in this study.

   There is a lack of published data on the metabolism of phenolic substances, and particularly polyphenols, in mouse lemurs, although experiments are ongoing in the wild in Madagascar to assess the amounts of different phenolic substances ingested daily and seasonally in these primates. Up until now, we have had no evidence indicating any difference in the metabolism of males and females.

   The mouse lemurs in our study were given 200 mg.kg$^{-1}$ of resveratrol by gavage. A dose of 200 mg.kg$^{-1}$ of body weight has been previously given to grey mouse lemur in the Restrikal project; the first results exhibited a physiological effect from this dose of resveratrol [20,21]. In the present study, resveratrol (20 mg.mL$^{-1}$) was administered within the homemade food mixture. Blood samples were taken via the saphenous vein, without anaesthesia, at the end of the resting phase but before food became available. Blood samples (100–150 µL) were collected in tubes containing EDTA. They were then centrifuged at 2000 g at 4°C for 30 min. Before storage of the plasma at $-80^\circ$C, the samples underwent a second centrifugation at 2000 g at 4°C for 10 min.

3. **Plasma samples used for quantification**

   The blank plasma samples used for calibration standards and quality control samples were obtained from Swiss mice ($n=20$), provided by Janvier (Le Genest-St-Isles, France), and used for a study entitled “Measurement of resveratrol in mouse tissues by UHPLC-Q-TOF,” which has been approved by the Ethical Committee of the University Paris Descartes, and is registered as number CEEA34.CH.C.043.11.

4. **Quantification and study design**

   The method used to quantify resveratrol and its sulfo- and glucuronido-derivatives has been previously validated in mouse plasma and has been described in detail elsewhere [11]. Briefly, initial standard-stock solutions of trans-resveratrol, trans-resveratrol-4’-O-ß-D-glucuronide, trans-resveratrol-3-O-ß-D-glucuronide, and trans-resveratrol-3-sulfate, as well as initial corresponding internal
standard-stock solutions, were prepared in MeOH at 5 mg.mL$^{-1}$. For calibration standards, different stock solutions that combined all four compounds were then prepared in a mixture of ACN/water (20/80; V/V) at concentrations of 20 times higher than those of the calibration standards, i.e., between 0.5 and 320 μmol.L$^{-1}$. The final internal standard-stock solution, combining all four internal standards, with concentrations of 40 μmol.L$^{-1}$ each of trans-resveratrol-3-sulfate-D4 and trans-resveratrol-13C6, and 200 μmol.L$^{-1}$ each of trans-resveratrol-4-9-O-ß-D-glucuronide-D4 and trans-resveratrol-3-O-ß-D-glucuronide-D4, was prepared in the ACN/water (20/80; V/V) mixture.

5. Extraction of resveratrol and its metabolites from plasma

Plasma samples were prepared according to Menet et al. [11]. Briefly, 50 μL of untreated mouse plasma spiking by analyte standards or 50 μL of treated lemur plasma, were vortex-mixed with the internal standard solution and 200 μL of ACN for 20 s. They were then let to stand for 20 min and centrifuged at 1000 g for 10 min. Supernatants were separated and evaporated to dryness using a Speed Vac Concentrator (Savant, SPD131DDA, Thermo Fischer Scientific, Les Ulis, France). The dried extracts were reconstituted in 50 μL of ACN/water/formic acid (20/80/0.1; V/V/V).

6. Ultra-high performance liquid chromatography–mass spectrometry conditions and instrumentation

The conditions for analyses were the same as described by Menet et al. [11]. Samples were injected into an Acquity UPLC system (Waters, Manchester, UK), equipped with an Acquity UHPLC BEH C18 column (50 x2.1 mm inner diameter, particle size 1.7 μm), which was purchased from Waters (Guyancourt, France). The mobile phase consisted of mixture of water and ACN. It was operated with a flow-rate of 0.4 mL/min in gradient mode, at a temperature of 30°C. Mass spectra were recorded with a Waters Synapt G2 HDMS mass spectrometer (Waters, Manchester, UK). Measurements were performed using negative electrospray ionization (ESI) in full-scan data-acquisition mode. The parameters of the electrospray interface were optimized to provide the highest abundance of the [M–H]$^{-}$ ion for all analytes and internal standards.

MSE method (centroid) was used to identify the metabolites. The scan time was set at 0.1 s. All data were lock-mass connected with the pentapeptide–leucine enkephalin, Tyr–Gly–Gly–Phe–Leu ([M–H]$^{-}$ at m/z 554.2615), in a ACN/water/formic acid (50/50/0.1; V/V/V) solution (2 ng.μL$^{-1}$). Calibration of the Synapt G2 mass spectrometer in the range of m/z 50–1200 was performed using a solution of sodium formate (5 mmol.L$^{-1}$) in 2-propanol/water (9/1; V/V).

For each compound, the [M–H]$^{-}$ ion was used for quantification, according to the quantification method described by Menet et al. [11]. Indeed, this study has shown that, such as Stark et al. [25], the performances of the UHPLC–Q-TOF (i.e. high-resolution mass spectrometer) combined with SIDA (stable isotope dilution analysis), compared with HPLC-MRM-MS combined with SIDA, are similar in terms of quantification.

Data processing was performed using MassLynx software (V 4.1, SCN 779, Waters, Manchester, UK) and the elemental composition tool. The QuanLynx (V 4.1, SCN 803, Waters) was used to detect and integrate the peaks of the [M–H]$^{-}$ ions at m/z 227.07 (trans-resveratrol), m/z 233.09 (trans-resveratrol-13C6), m/z 403.10 (trans-resveratrol-3-O-ß-D-glucuronide), and trans-resveratrol-3-O-ß-D-glucuronide-D4, or trans-resveratrol-3-O-ß-D-glucuronide-D4 (R1 = R2 = R3 = R4 = D).
trol-4'-O-ß-D-glucuronide); m/z 407.13 (trans-resveratrol-3-O-ß-D-glucuronide-D4), and trans-resveratrol-4'-O-ß-D-glucuronide-D4); m/z 307.03 (trans-resveratrol-3-sulfate), m/z 311.05 (trans-resveratrol-3-sulfate-D4), m/z 483.06 (trans-resveratrol-glucuronide-sulfate derivatives), m/z 495.08 (DHR-glucuronide-sulfate derivative), m/z 405.12 (DHR-glucuronide), and m/z 309.04 (DHR-sulfate).

7. Determination of resveratrol and its metabolites in plasma samples from resveratrol-treated grey mouse lemurs

Plasma samples from mouse grey lemurs treated with trans-resveratrol were assayed and the concentrations of trans-resveratrol and its metabolites measured from the peak-area ratios of the analytes and internal standards. These ratios were used to calculate the concentrations of compounds within the plasma specimens from the calibration curves, which were prepared as described above. Quality control samples were included in each analytical batch to check for calibration, accuracy, and precision.

The retention times of trans-resveratrol-glucuronide-sulfate derivatives (2.05 and 2.32 min) as well as the DHR-glucuronide-sulfate derivative (2.05 min) were close to that of trans-resveratrol-4'-O-ß-D-glucuronide (2.28 min). As the standards and internal standards of these compounds are not available, their concentrations were estimated by using trans-resveratrol-4'-O-ß-D-glucuronide-D4 as internal standard and the corresponding calibration concentration. Concentrations were expressed as trans-resveratrol 4'-O-ß-D-glucuronide equivalents.

The retention time of DHR-glucuronide (3.49 min) was close to that of trans-resveratrol-3-O-ß-D-glucuronide-D4 (2.93 min), and the retention time for DHR-sulfate (3.88 min) was close to that of trans-resveratrol-3-sulfate (3.86 min). As the standards and internal standards for DHR derivatives are not available, their concentrations were estimated using trans-resveratrol-3-O-ß-D-glucuronide-D4 and trans-resveratrol-3-sulfate-D4 as internal standards for DHR-glucuronide and DHR-sulfate respectively and the corresponding calibration curves. Concentrations were, respectively, expressed as equivalents of trans-resveratrol-3-O-ß-D-glucuronide and trans-resveratrol-3-sulfate.

Results and Discussion

1. Identification of resveratrol and its metabolites

Resveratrol and its metabolites have been identified through UHPLC coupled to Q-TOF mass spectrometry (SynaptG) in MSÈ mode. The latter allows accurate monoisotopic masses (lower than 10 ppm) to be recorded at high- and low-collision energies successively. The first recording allows the m/z ratio of the pseudo-molecular ion [M–H]⁻ to be obtained, while the second recording displays the m/z ratio of the daughter ions. Thus, UHPLC-Q-TOF-MSÈ is a powerful tool to analyze complex mixtures, especially biological fluids, and enables to obtain the elucidation of elemental composition and fragmentation information [26].

Herein, the composition of mouse-lemur plasma was analyzed with this new approach, which permitted the structures of several endogenous components to be confirmed in one analytical run by the simultaneous acquisition of exact masses of precursor and daughter ions.

The identification of resveratrol and resveratrol metabolites in samples was made in two steps. First at all, UPLC-Q-TOF-MSÈ analysis of standards, trans-resveratrol-3-O-ß-D-glucuronide, trans-resveratrol-4'-O-ß-D-glucuronide, trans-resveratrol-3-sulfate, and trans-resveratrol enabled to obtain their retention time and their spectra at low- and high-collision energies. Trans-resveratrol-4'-O-

β-D-glucuronide had a retention time of 2.28 min, trans-resveratrol-3-O-ß-D-glucuronide of 2.93 min, trans-resveratrol-3-sulfate of 3.86 min, and trans-resveratrol of 4.35 min. Figure 2 shows the high-collision energy spectrum obtained after the fragmentation of the pseudo-molecular ion m/z 227.072 (as a result of resveratrol ionization in the ESI source) and the m/z ratios of the daughter ions, 143.050 and 185.061, which correspond to the elemental composition of each ion, C₉H₇O₅ (143.050) and C₁₂H₁₂O₅ (185.061), respectively. The same fragmentation pattern was encountered for hydrophilic metabolites.

Figure 3 shows spectra obtained at low- and high-collision energies for the pseudo-molecular ion m/z 403.102, which is characteristic of monoglucuronato-conjugated derivatives. The low-energy spectrum shows that the glucurono moiety was lost easily, with the emergence of a m/z 227.070 ion. The high-collision energy spectrum shows the presence of all daughter ions that are the characteristic of m/z 227.071, i.e., m/z 143.050 and 185.060, together with the ions characteristic of glucurono-conjugated derivatives, m/z 175.024 (C₉H₇O₄) and 113.024 (C₅H₇O₃), resulting from the rearrangement of the previous ion m/z 175.024 (Fig. 3) [27]. The same kind of spectra has been obtained with trans-resveratrol-3-sulfate, with the loss of the sulfo moiety and fragmentation of the resulting m/z 227.072 ion.

The results for precursor and daughter ions in the four standards studied are reported in Table 1. The averages of m/z values were determined after five injections of standard mixtures at 6, 8, and 16 μmol L⁻¹ in UHPLC-Q-TOF. The mass accuracy for all ions was lower than 10 ppm, from lower than 1 to 8.8 ppm. These results highlight that the accuracy of mass determination of the daughter ions enabled their structures to be confirmed, as reported in the literature [28,29]. These data were compared to those recorded after analyzing the treated mouse lemur plasmas where trans-resveratrol-3-O-ß-D-glucuronide, trans-resveratrol-4'-O-ß-D-glucuronide, trans-resveratrol-3-sulfate, and resveratrol were found (Table 1). The mass accuracy for all ions was lower than 10 ppm. Thus, the metabolites were identified by their retention time and the presence of specific ions in their high-collision energy spectrum, i.e., m/z 143.050, 185.060, and 227.071, except for trans-resveratrol-4'-O-ß-D-glucuronide. For the latter, in the sample plasma chromatograms, the intensity of the pseudo-molecular ion m/z 403.099 was low; consequently, the daughter ions, m/z 143.050 and 185.060, were not detected. Therefore, this compound was identified by the presence of ions m/z 403.099, 227.069, and 113.023, with accuracy lower than 10 ppm, i.e., 9.9, 8.8, and 8.8 ppm, respectively. Generally, accuracy was lower (values close to 10 ppm) when the ion intensity was low.

Our study has shown the easy loss of glucurono- and sulfo-moieties of conjugated derivatives, with the emergence of the m/z 227.072 ion in low-collision energy spectra. This result was used to find other possible glucurono- and/or sulfo-conjugated derivatives in mouse-lemur plasma, according to a semi-targeted mode. The variation in intensity of the m/z 227.071 ion obtained at high-collision energy, versus time is shown in figure 4a, for plasma obtained 2 h after intake. This chromatogram shows the presence of trans-resveratrol-3-O-ß-D-glucuronide and trans-resveratrol-3-sulfate, together with other glucurono- and/or sulfo-conjugated derivatives with retention times close to 1.30 and 2 min, respectively. Figure 4a also shows the high-collision energy spectrum at 2.05 min. Ions corresponding to a both glucurono- and sulfo-conjugated derivative are noted m/z 483.059, together with m/z 307.028 and 403.103, appeared after the loss of glucurono- and sulfo-moieties, respectively. The daughter ions specific to resveratrol, m/z 143.049 and 185.060, were also...
detected at the same retention time. The 2.32-min spectrum displays the same characteristics. Table 1 shows the averages \( m/z \) ratio and a satisfactory accuracy value (\( \leq \)10 ppm) for each ion. The 1.30-min spectrum shows the \( m/z \) 579.135 ion after ionization of a di-glucurono-conjugated derivative (spectrum not shown). The ion intensity is weak; consequently, the daughter ions, \( m/z \) 403.101, 227.072, and 113.024, appear in the high-energy collision spectrum, but not \( m/z \) 143.050 and 185.060. The identification of this compound was confirmed by the accuracy of the \( m/z \) values, i.e., 0.9, \(-4.7,\) and \(-4.4 \) ppm for, respectively, \( m/z \) 579.135, 403.103, and 227.071. This derivative was present in mouse-lemur plasma, but at a very low concentration. This was confirmed by the quantitative study described in the next paragraph; the concentrations of this metabolite in the plasmas of all mouse lemurs were below the lower limit of quantification and, therefore, are not listed in Tables 1 and 2.

Thus, mouse-lemur plasmas contained monoglucurono-, mono-sulfo-, di-glucurono-, and both glucurono- and sulfo-conjugated...
derivatives as the main resveratrol metabolites. All these derivatives have already been detected in mouse [11], pig [14,30], and human [31,32] plasmas. Some have been found in the rat [9,12,33] and dog [13]. However, results are difficult to compare because of the heterogeneous conditions that have been used for resveratrol administration (see table 3).

In the human gut, part of resveratrol is metabolized into DHR [34]. After resveratrol consumption, this compound [35,36] and its metabolites [27] can be retrieved from human plasma. They have been also detected in pig [14] and rat [37] tissues. The pseudomolecular DHR ion (C14H13O3) is the m/z 229.087 ion. A low-intensity ion, m/z 229.072, was found in data obtained with plasma 1, 2, and 6 h after intake: this corresponded to the m/z +2 of isotopic mass of the 227.072 ion (Fig. 2). Herein, DHR was not present in these mouse lemur plasmas. In contrast, in plasma at 24 h after intake, DHR metabolites were detected.

Figure 4b shows the variation in intensity of the m/z 229.086 ion obtained at high-collision energy versus time. This chromatograms

| Compound | Ion Formula | Theoretical mass | Standard m/z (ppm)/metabolite m/z (n, ppm) |
|----------|-------------|------------------|------------------------------------------|
| RGS      | C20H19O12S | 483.059          | 483.060 (34, 2)                           |
|          | C20H19O9   | 403.103          | 403.099 (32, −9.9)                        |
|          | C14H11O6S  | 307.027          | 307.029 (32, 6.5)                         |
|          | C14H11O3   | 227.071          | 227.069 (30, −8.7)                        |
|          | C12H9O2    | 185.060          | 185.061 (21, 5.4)                         |
|          | C14H10      | 143.050          | 143.049 (16, −7.0)                        |
|          | C9H7O       | 113.024          | 113.023 (24, −8.8)                        |
| 4’RG     | C20H19O9   | 403.103          | 403.102 (−2.5)/403.099 (20, −9.9)         |
|          | C14H11O3   | 227.071          | 227.070 (−4.4)/227.069 (19, −8.8)         |
|          | C12H9O2    | 185.060          | 185.061 (7, 5.4)                          |
|          | C14H10      | 143.050          | 143.049 (5, −6.9)                         |
|          | C9H7O       | 113.024          | 113.023 (−8.8)/113.023 (20, −8.8)         |
| 3RG      | C20H19O9   | 403.103          | 403.103 (0.5)/403.102 (34, −2.5)          |
|          | C14H11O3   | 227.071          | 227.070 (−4.4)/227.072 (34, 4.4)          |
|          | C12H9O2    | 185.060          | 185.061 (5.4)/185.058 (27, −9.9)          |
|          | C14H10      | 143.050          | 143.050 (1.1)/143.049 (27, −7.0)          |
|          | C9H7O       | 113.024          | 113.025 (8.8)/113.023 (28, −8.8)          |
| RS       | C14H11O6S  | 307.027          | 307.028 (4.0)/307.028 (34, 3.6)           |
|          | C14H11O3   | 227.071          | 227.071 (1.0)/227.073 (34, 8.8)           |
|          | C12H9O2    | 185.060          | 185.059 (−3.6)/185.060 (27, 1.4)          |
|          | C14H10      | 143.050          | 143.050 (0.9)/143.050 (27, −1.1)          |
|          | C9H7O       | 113.024          | 113.020 (−8.8)                            |
|          | C10H7O      | 143.050          | 143.050 (−0.6)                            |
|          | C5H5O3     | 113.024          | 113.025 (8.8)                            |
| DHRGS    | C20H21O12S | 485.076          | 485.076 (8, 0.7)                          |
|          | C20H21O9   | 405.119          | 405.118 (8, −2.4)                         |
|          | C14H13O6S  | 309.044          | 309.044 (8, 0.9)                          |
|          | C14H13O3   | 229.087          | 229.085 (8, −8.7)                         |
|          | C7H7O2     | 123.045          | 123.045 (4, −0.8)                         |
|          | C5H5O3     | 113.024          | 113.023 (7, −8.8)                         |
| DHRG     | C20H21O9   | 405.119          | 405.118 (8, −2.4)                         |
|          | C14H13O3   | 229.087          | 229.085 (8, −8.7)                         |
|          | C7H7O2     | 123.045          | 123.044 (3, −8.1)                         |
|          | C5H5O3     | 113.024          | 113.025 (8, 8.8)                          |
| DHRS     | C14H13O6S  | 309.044          | 309.045 (8, 3.5)                          |
|          | C14H10      | 229.087          | 229.086 (8, −4.4)                         |
|          | C10H7O      | 123.045          | 123.045 (8, −0.8)                         |

RGS = trans-resveratrol-glucuronide-sulfate; 4’RG = trans-resveratrol-4’-O-ß-glucuronide; 3RG = trans-resveratrol-3-O-ß-glucuronide; RS = trans-resveratrol-sulfate, R = resveratrol; DHRGS = DHR-glucuronide-sulfate; DHRG = DHR-glucuronide; DHRS = DHR-sulfate.

Standard samples: 3×5 injections; plasma samples: 17×2 injections.
n: Number of injections where an ion was found.

doi:10.1371/journal.pone.0091932.t001
gram shows the presence of one DHR-glucuronide with a retention time of 3.49 min, one DHR-sulfate with a retention time of 3.88 min, and one both glucurono- and sulfo-conjugated derivative with a retention time of 2.05 min. Figure 4b also shows the high-collision energy spectrum at 2.05 min. Ions corresponding to one both glucurono- and sulfo-conjugated derivative are noted m/z 485.074 together with m/z 309.043 and 405.118, appeared after the loss of the glucurono and sulfo moiety respectively. The daughter ion specific to DHR m/z 123.045 was also detected at the same retention time [28]. Table 1 shows the average m/z ratio with a satisfactory accuracy value (lower than 10 ppm) for each ion. Identification of these metabolites is not totally complete because our data did not allow us to know the position(s) of the sulfo and/or glucurono moieties.

To sum up, nine resveratrol derivatives were identified in mouse-lemur plasma samples by using UHPLC–Q-TOF–MS E and a semi-targeted approach. High-resolution mass spectrometry, Q-TOF, confirmed the structures of ions and their elemental compositions. These results, obtained by UPLC–Q-TOF–MS E, are complementary to those already described in the literature, where compounds have been identified by liquid chromatography coupled to a diode-array detector [12] or a low-resolution mass spectrometer, such as an ion trap [12] or a triple quadrupole [28]. The ion trap confirms the compound presence by displaying the MS² spectrum; the triple quadrupole identifies the molecules according to their specific transitions (parent/daughter ions) in MRM mode [38,39] and, in our work, Q-TOF confirmed the presence of the compounds by measuring the exact ratio m/z of the parent and daughter ions.

2. Quantification of resveratrol and its metabolites

A full validation of the quantification method requires a large volume of plasma from untreated lemurs, i.e., ~15 mL of plasma (30 mL of blood), which would require killing about 10 lemurs: this is a far too high number and poses an ethical problem. Therefore, in this study, we examined the eventual analysis interferences from the grey mouse lemur plasma by analyzing, with the quantification method [11], the plasma of three lemurs not treated with resveratrol. No interference was present at the retention times for the compounds tested. Thus, we used this quantification method validated in mice and described by Menet at al. [11] to quantify the compounds in the plasma from grey mouse lemurs since the mouse plasma, like that from lemurs, contained no interference that could disturb determination of the compounds.

The design of this study was not to carry out a pharmacokinetic study but, rather, to be a preliminary study on resveratrol metabolism in this lemur. Indeed, a complete pharmacokinetic study would have required many more animals as it is impossible to collect more than 150 μL of plasma per animal (i.e., 10% of total plasma volume).

Previous studies in various species have shown that intestinal absorption of free trans-resveratrol is complex [40] and is limited by its rapid metabolism in enterocytes to yield glucuronide and sulfate (trans-resveratrol-3-O-ß-D-glucuronide and trans-resveratrol-3-sulfate) which are subsequently excreted through ABC membrane proteins [41]. In our study, the concentrations of trans-resveratrol and its main identified metabolites, trans-resveratrol-3-O-ß-D-glucuronide, trans-resveratrol-4’-O-ß-D-glucuronide, trans-
Resveratrol-3-sulfate, two trans-resveratrol glucuronide sulfates, DHR-glucuronide-sulfate, DHR-glucuronide and DHR-sulfate were determined in the plasma from male mouse-lemurs at 1, 2, 6, and 24 h after intake of 200 mg.kg\(^{-1}\) of resveratrol, equivalent to 14 g/70 kg in humans (Table 2).

Free trans-resveratrol was present in the plasma in the first hour and 2 h after intake, at concentrations of 5.61 (CV 77.6%) and 1.25 (CV 75.6%) \(\mu\)mol.L\(^{-1}\), respectively (Table 2). It also remained measurable after 6 and 24 h. However, trans-resveratrol was rapidly metabolized into two main metabolites. The most concentrated metabolite was trans-resveratrol-3-O-ß-D-glucuronide, whereas trans-resveratrol-3-sulfate was six times less concentrated. The prevalence of these two metabolites has been found in several species, such as mouse [11] and pig [14,30]. This result is less clear in rat [33,42] and dog [13,43] (see Table 3). However, when high doses of the pure resveratrol trans-isof orm are administered, resveratrol sulfate derivatives have been found to be the main metabolites in humans [32,38,39,44,45,46,47]. Sometimes, glucuronide derivatives have been the major metabolites, but only after low doses of resveratrol intake [38,48,49]. However, optimization of bioavailability may favor the presence of the sulfate form at the

| Table 2. Concentrations of trans-resveratrol and its hydrophilic metabolites and hydrophilic metabolites of dihydro-resveratrol (DHR). |
|---|
| **1 h \((n=4)\)** | **2 h \((n=5)\)** | **6 h \((n=4)\)** | **24 h \((n=4)\)** |
| **Trans-resveratrol glucuronide sulfate** 1 | 1.87 (57.18) | 3.89 (120.88) | 1.25 (27.44) | 0.49 (60.55) |
| [0.78–3.34] | [0.91–12.24] | [0.93–1.72] | [0.25–0.92] |
| **Trans-resveratrol glucuronide sulfate** 2 | 0.41 (39.99) | 0.73 (102.10) | 0.30 (7.45) | 0.31 (59.34) |
| [0.22–0.61] | [0.28–2.06] | [0.27–0.47] | [0.16–0.56] |
| **Trans-resveratrol-4’-O-ß-glucuronide** | 0.64 (100.89) | 0.88 (73.75) | 0.39 (35.17) | 0.05 (210.00) |
| [<= LLOQ-1.54] | [0.46–2.03] | [0.30–0.60] | [<= LLOQ-0.21] |
| **Trans-resveratrol-3-O-ß-glucuronide** | 227.04 (34.98) | 111.74 (32.67) | 72.43 (41.02) | 5.52 (73.52) |
| [169.13–342.81] | [64.81–152.02] | [31.32–98.84] | [1.40–10.43] |
| **Trans-resveratrol-3-sulfate** | 36.93 (43.61) | 18.64 (27.77) | 9.35 (13.50) | 1.19 (69.19) |
| [24.89–60.12] | [12.43–26.25] | [8.23–11.08] | [0.45–2.12] |
| **Trans-resveratrol** | 5.61 (77.59) | 1.25 (75.66) | 0.60 (72.28) | 0.29 (198.28) |
| [2.16–11.51] | [0.41–2.87] | [<= LLOQ-1.01] | [<= LLOQ-1.15] |
| **DHR-glucuronide-sulfate** | / | / | / | 8.94 (52.68) |
| / | / | / | [4.17–13.64] |
| **DHR-glucuronide** | / | / | / | 47.31 (30.96) |
| / | / | / | [33.68–67.93] |
| **DHR-sulfate** | / | / | / | 6.98 (20.44) |
| / | / | / | [5.77–9.03] |

Mean values in \(\mu\)mol.L\(^{-1}\). Values expressed as “trans-resveratrol-4’-O-ß-glucuronide equivalent” for trans-resveratrol glucuronide sulfate and DHR-glucuronide sulfate; as “trans-resveratrol-3-O-ß-glucuronide equivalent” for the DHR-glucuronide and as “trans-resveratrol-3-sulfate equivalent” for the DHR-sulfate. CV% between mouse lemurs (round brackets), range (square brackets). There were three determinations for each concentration. \(n\): sample size. LLOQ: lower limit of quantification. doi:10.1371/journal.pone.0091932.t002

| Table 3. Main resveratrol metabolites after a single dose of pure trans-resveratrol administration in different species. |
|---|
| **citation** | **model** | **administration** | **Dose** | **Type of study** | **Two main metabolites** |
| [11] mouse Oral 150 mg.kg\(^{-1}\) | 30 and 60 min after administration | 3RG>3RS |
| [30] pig intragastric 6.25 mg.kg\(^{-1}\) | pharmacokinetic study 0—300 min | 3RG>3RS |
| [14] pig intragastric 6.25 mg.kg\(^{-1}\) | 6 h after administration | 3RG>3RS |
| [43] Dogs oral 200 mg.kg\(^{-1}\) | pharmacokinetic study 0—24 h | RS>RG |
| oral 600 mg.kg\(^{-1}\) | pharmacokinetic study 0—24 h | RG>RS |
| oral 1200 mg.kg\(^{-1}\) | pharmacokinetic study 0—24 h | RG>RS |
| [33] rats oral 50 mg.kg\(^{-1}\) | pharmacokinetic study 0—24 h | RG>RS |
| rats oral 150 mg.kg\(^{-1}\) | pharmacokinetic study 0—24 h | RS>RG |
| [42] rats IV 15 mg.kg\(^{-1}\) | pharmacokinetic study 0—720 min | RG>RS |
| [46] human Oral 0.5 g—5 g | pharmacokinetic study 0—24 h | 3RS>RG |

RG = resveratrol-glucuronide; 3RG = trans-resveratrol-3-O-glucuronide; RS = trans-resveratrol-sulfate; 3RS = trans-resveratrol-3-O-sulfate. doi:10.1371/journal.pone.0091932.t003
expense of glucuronide derivatives, even with low doses of resveratrol [50].

The trans-resveratrol-4'-O-ß-glucuronic acid was also present and quantifiable in most mouse-lemur plasmas. The presence of this metabolite has been previously reported in humans. When resveratrol was ingested through moderate consumption of red wine, glucurono conjugation in the 3 or 4' position has been shown to be significant in metabolism [47], but seems to differ significantly according to the individual [51]. However, trans-resveratrol-4'-O-ß-glucuronic acid in the mouse lemur represents a minor metabolism pathway compared to conjugation in position 3. As already reported in mice [11], the hydroxyl moiety at position 3 is probably the main position for conjugation. Moreover, regarding these data, trans-resveratrol glucuronide sulfate derivatives, found in small quantities in plasma, could arise from the sulfo-conjugation of trans-resveratrol 3-O-glucuronide and glucuronono-conjugation of trans-resveratrol-sulfate. Indeed concentrations of these metabolites are highest at 2 h after resveratrol intake, whereas concentrations of 3-mono-conjugated metabolites are highest at 1 h after intake.

DHR was not present whatever the time of collection, and the hydrophilic metabolites of DHR were only found at 24 h after intake at a concentration of 47.3 µmol.L\(^{-1}\) (CV 31.0%) for the most concentrated compound, i.e., DHR-glucuronide. DHR is supposed to be a result of metabolism by gut microflora [34]. Our study did not investigate the metabolites produced between 6 and 24 h after resveratrol absorption. Therefore we cannot exclude the possibility of the presence of DHR in plasma during this period. Of note, an enterohelical cycle has been evoked for resveratrol in rats [52] and in humans [27,46], leading to delayed delivery of resveratrol in the gut. Moreover, DHR, when orally administered in rats, is absorbed and metabolized into DHR glucuronide and sulfate [9]. Thus, we can hypothesize that the presence of DHR metabolites in plasma samples only at 24 h was the result of late gut transformation of resveratrol into DHR, of DHR absorption and subsequent DHR metabolism into DHR glucuronide and sulfate. However, resveratrol, particularly when high doses are administered, may, by its antibacterial properties, affect the gut’s bacterial profile and thus the rate of gut metabolism [33]. Further studies are needed to investigate these issues.

Intake of resveratrol at 200 mg.kg\(^{-1}\) may appear high for a study on metabolism, but this dose has been safety used for a long period in the Resrikal project [20,21]. Moreover, higher doses have been reported to be well tolerated in rats and rabbits [54,55]. The dose of 200 mg.kg\(^{-1}\) corresponds to about 14 g/70 kg of human bodyweight. Several clinical trials have been performed with good tolerance of doses of up to 5 g per day, which is not far from the 14 g/70 kg of bodyweight given to humans [44,56]. With high repeated doses, mild to moderate gastrointestinal disorders have been reported in humans, mainly diarrhea [16]. Thus, we cannot exclude that the use of 200 mg.kg\(^{-1}\) resveratrol may alter, at least in part, gastrointestinal absorption, which may then impact its metabolism. However, in the design of our study, because each lemur only received one dose, it seems unlikely that this would lead to significant modification of resveratrol metabolism and absorption.

Conclusion

Resveratrol and its metabolites were identified in Microcebus murinus plasma after oral intake of 200 mg.kg\(^{-1}\) of resveratrol using UHPLC coupled to a Q-TOF mass spectrometer (Synapt\(^{\text{R}}\)) in MS\(^{2}\) mode. Resveratrol treatment led to the presence of quantifiable free resveratrol in the plasma over a 24-h period in the grey mouse lemur. Six hydrophilic metabolites of resveratrol and three hydrophilic metabolites of DHR were identified, and, among them, the two main metabolites were trans-resveratrol-3-O-glucuronide and trans-resveratrol-3-sulfate.

However, although the grey mouse lemur is phylogenetically closer to humans than to rodents and, in many respects, is a relevant model for studying ageing, it appears that its resveratrol-metabolism profile is nearer to mouse than to humans. These data will be useful when interpreting the effect of resveratrol in the mouse lemur and will provide further information about the interspecies characteristics of resveratrol metabolism.

Author Contributions

Conceived and designed the experiments: MCM JM ADP VNA JLB FA JE CHC. Performed the experiments: MCM JM MT DD CHC. Analyzed the data: MCM CHC. Contributed reagents/materials/analysis tools: MCM JM ADP VNA JLB FA JE CHC. Wrote the paper: MCM JM FA JE CHC.

References

1. Beaudeux JL, Nivet-Antoine V, Giral P (2010) Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Curr Opin Clin Nutr Metab Care 13: 729-736.
2. Frombaum M, Le Clanche S, Bonnefont-Rousselot D, Borderie D (2012) Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and *NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie 94: 209-276.
3. Petrovski G, Gurumamy N, Das DK (2011) Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 1215: 22-33.
4. Richard T, Pavlus AD, Iglesias ML, Pedrot E, Waffo-Teguo P, et al. (2011) Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 1215: 105-108.
5. Li F, Gong Q, Dong H, Shi J (2012) Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des 18: 27-33.
6. Shukla Y, Singh R (2011) Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 1215: 1-8.
7. Hu Y, Liu J, Wang J, Liu Q (2011) The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radic Biol Med 51: 250-256.
8. Agarwal B, Baur JA (2011) Resveratrol and life extension. Ann N Y Acad Sci 1215: 130-143.
9. Juan ME, Alfarcas I, Planas JM (2010) Determination of dihydroresveratrol in rat plasma by HPLC. J Agric Food Chem 58: 7472-7475.
10. Meaur-Salamon A, Bohndorfer M, Thalhammer T, Szekeres T, Jaeger W (2011) Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog. Drug Metab Pharmacokinet 26: 364-373.
11. Menet MC, Cottart CH, Taghi M, Nivet-Antoine V, Dargere D, et al. (2013) Ultra high performance liquid chromatography-quadrupole-time of flight analysis for the identification and the determination of resveratrol and its metabolites in mouse plasma. Anal Chim Acta 761: 128-136.
12. Wenzel E, Seldt T, Erbesdohler H, Somova Z (2005) Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49: 402-494.
13. Muzzio M, Huang Z, Hu SC, Johnson WD, McCormick DL, et al. (2012) Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. J Pharm Biomed Anal 59: 201-208.
14. Azorin-Orruno M, Yanez-Gascon MJ, Vallejo F, Pallares EF, Laraosa M, et al. (2011) Metabolites and tissue distribution of resveratrol in the pig. Mol Nutr Food Res 55: 1154-1168.
15. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL (2010) Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54: 7-16.
16. Cottart CH, Nivet-Antoine V, Beaudeux J (2014) Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res 58: 7-21.
17. Dal-Pan A, Pifferi F, Marchal J, Piquet JL, Ajard F (2011) Cognitive performances are selectively enhanced during chronic calorie restriction or resveratrol supplementation in a primate. PLoS One 6: e16581.
18. Languille S, Blanc S, Blin O, Canale CI, Dal-Pan A, et al. (2012) The grey mouse lemur: a non-human primate model for ageing studies. Ageing Res Rev 11: 150-162.
19. Marchal J, Dal-Pan A, Epelbaum J, Blanc S, Mueller S, et al. (2013) Caloric restriction and resveratrol supplementation prevent age-related DNA and RNA oxidative damage in a non-human primate. Exp Gerontol 48: 992–1000.

20. Dal-Pan A, Terrien J, Pifferi F, Botella R, Hardy I, et al. (2011) Caloric restriction, resveratrol supplementation and aging in a non-human primate: first-year outcome of the RESTRIKAL study in Macaca mulatta. Age (Dordr) 33: 15–31.

21. Marchal J, Blanc S, Epelbaum J, Aujard J, Pifferi F, et al. (2012) Effects of Chronic Calorie Restriction on the Bioavailability of Resveratrol Supplementation on Insulin Sensitivity Markers in a Primate, Macaca mulatta. PLoS One 7: e34289.

22. Dal-Pan A, Blanc S, Aujard JF (2010) Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 10: 11.

23. Filleri F, Rahman A, Langille S, Auffret A, Bahioun C, et al. (2012) Effects of dietary resveratrol on the sleep-wake cycle in the non-human primate gray mouse lemur (Microcebus murinus). Chronobiol Int 29: 261–270.

24. Camont I, Cottrat CH, Pham-Nguyen T, Krajci G, Djeffal R, et al. (2009) Simple spectrophotometric assessment of the trans/cis-resveratrol ratio in aqueous solutions. Anal Chim Acta 634: 121–128.

25. Stark T, Wolffmann N, Losch S, Hofmann T (2011) Quantitation of resveratrol in red wines by means of stable isotope dilution analysis-ultra-performance liquid chromatography-Quan-time-of-flight mass spectrometry and cross validation. Anal Chem 83: 3398–3405.

26. Barbara JE, Kaezi F, Muranjan S, Toren PC, Parkinson A (2012) High-resolution mass spectrometry elucidates metabolites (false metabolites) formation from alkyamine drugs during in vitro metabolic profiling. Drug Metab Dispos 40: 1966–1975.

27. Walle T, Huich F, DeLegge MH, Otsen JE, Jr, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377–1382.

28. Wang D, Hong M, Wu CF, Liu W (2005) Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 829: 97–106.

29. Shu XH, Li H, Sun Z, Wu ML, Ma JX, et al. (2010) Identification of metabolite pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol 79: 1516–1525.

30. Azorin-Orozno M, Yanez-Gascon MJ, Pallares EJ, Vallejo F, Larrosa M, et al. (2010) Pharmacokinetic Study of trans-Resveratrol in Adult Pigs. J Agric Food Chem 58: 1513–1517.

31. Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, et al. (2007) Quantitation of trans-resveratrol and detection of its metabolites in plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 848: 182–187.

32. Burkon A, Somora V (2008) Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides – two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 52: 549–557.

33. Kapetanovic IM, Muzzio MJ, Huang Z, Thompson TN, McCormick DL (2011) Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 67: 593–601.

34. Bode LM, Bunzel D, Huch M, Cho GS, Ruhland D, et al. (2013) In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr 97: 295–309.

35. Yoshida J, Conte C, Fontana L, Mittendorf B, Inami SL, et al. (2012) Resveratrol Supplementation Does Not Improve Metabolic Function in Nonobese Women with Normal Glucose Tolerance. Cell Metab 16: 638–644.

36. Timmers S, Konings E, Bleti L, Houtkooper RH, van de Weijer T, et al. (2011) Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans. Cell Metab 14: 612–622.

37. Andres-Lacueva C, Macarrua MT, Ritches-Ribalta M, Boto-Ordonez M, Urpi-Sarda M, et al. (2012) Distribution of resveratrol metabolites in liver, adipose tissue, and skeletal muscle in rats fed different doses of this polyphenol. J Agric Food Chem 60: 4833–4840.

38. Urpi-Sarda M, Zamora-Ros R, Lamuela-Raventos R, Cherubini A, Jauregui O, et al. (2007) HPLC-tandem mass spectrometric method to characterize resveratrol metabolites in humans. Clin Chem 53: 292–299.

39. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, et al. (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392–7399.

40. Delmas D, Aires V, Linaghe F, Dutartre P, Mazue F, et al. (2011) Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci 1215: 48–59.

41. Planas JM, Alfaro I, Colom H, Juan ME (2012) The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch Biochem Biophys 527: 67–73.

42. Juan ME, Majo M, Planas JM (2010) Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 51: 391–398.

43. Johnson WD, Morrissey RL, Usborne AL, Kapetanovic I, Crowell JA, et al. (2011) Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol 49: 3319–3327.

44. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, et al. (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003–9011.

45. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, et al. (2010) Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3: 1168–1175.

46. Boocock DJ, Faust GE, Patel KR, Schanas AM, Brown VA, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246–1252.

47. Retchis-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E, Urpi-Sarda M (2012) Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res 66: 372–382.

48. Zha W, Qin W, Zhang K, Rotthaus GE, Chen YC, et al. (2012) Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 64: 393–400.

49. Zamora-Ros K, Urpi-Sarda M, Lamuela-Raventos RM, Estruch R, Vazquez-Ajed M, et al. (2006) Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 52: 1373–1390.

50. Amiot MJ, Romier B, Anh Dao TM, Fancilidino R, Circoili J, et al. (2013) Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 95: 1283–1289.

51. Viaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, et al. (2005) Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 49: 365–369.

52. Marier JF, Vachon P, Greisas A, Zhang J, Moreau JP, et al. (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302: 369–374.

53. Jung CM, Henze TM, Schnackenberg T, Ekins SA, et al. (2009) Interaction of dietary resveratrol with animal-associated bacteria. FEMS Microbiol Lett 297: 266–273.

54. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol Sci 72: 614–619.

55. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J (2009) Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 47: 2170–2172.

56. Howell LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, et al. (2011) Phase I randomized, double-blind pilot study of micromanized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4: 1419–1425.